Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is one of the leading causes of cancer-related death worldwide. This is due to delayed diagnosis and resistance to traditional chemotherapy. Delayed diagnosis is often due to the broad range of non-specific symptoms that are associated with the disease. Resistance to current chemot...
Main Authors: | Áine Sally, Ryan McGowan, Karen Finn, Brian Michael Moran |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/10/2417 |
Similar Items
-
Phospho-Ser<sup>784</sup>-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor
by: Faliang Wang, et al.
Published: (2021-10-01) -
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
by: María Laura Gutiérrez, et al.
Published: (2021-09-01) -
Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs
by: Bangbo Zhao, et al.
Published: (2022-12-01) -
Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
by: Wanting Hou, et al.
Published: (2022-09-01) -
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
by: Tarak Chouari, et al.
Published: (2023-08-01)